A detailed history of Marcum Wealth, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Marcum Wealth, LLC holds 1,204 shares of VRTX stock, worth $567,228. This represents 0.05% of its overall portfolio holdings.

Number of Shares
1,204
Previous 1,178 2.21%
Holding current value
$567,228
Previous $552,000 1.27%
% of portfolio
0.05%
Previous 0.06%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$460.0 - $505.78 $11,960 - $13,150
26 Added 2.21%
1,204 $559,000
Q2 2024

Jul 02, 2024

BUY
$392.81 - $485.53 $785 - $971
2 Added 0.17%
1,178 $552,000
Q1 2024

Apr 10, 2024

SELL
$407.69 - $446.08 $6,523 - $7,137
-16 Reduced 1.34%
1,176 $491,000
Q4 2023

Jan 10, 2024

SELL
$343.0 - $410.68 $24,696 - $29,568
-72 Reduced 5.7%
1,192 $485,000
Q3 2023

Oct 10, 2023

SELL
$338.18 - $362.46 $1,690 - $1,812
-5 Reduced 0.39%
1,264 $439,000
Q2 2023

Jul 13, 2023

SELL
$314.42 - $351.91 $40,245 - $45,044
-128 Reduced 9.16%
1,269 $446,000
Q1 2023

Apr 19, 2023

SELL
$283.23 - $323.1 $15,860 - $18,093
-56 Reduced 3.85%
1,397 $440,000
Q4 2022

Jan 12, 2023

BUY
$285.76 - $321.48 $2,857 - $3,214
10 Added 0.69%
1,453 $0
Q3 2022

Oct 11, 2022

SELL
$273.83 - $305.53 $20,537 - $22,914
-75 Reduced 4.94%
1,443 $418,000
Q2 2022

Jul 14, 2022

SELL
$234.96 - $292.55 $11,513 - $14,334
-49 Reduced 3.13%
1,518 $428,000
Q1 2022

Apr 20, 2022

SELL
$221.42 - $260.97 $18,599 - $21,921
-84 Reduced 5.09%
1,567 $409,000
Q4 2021

Feb 01, 2022

SELL
$177.01 - $223.45 $17,701 - $22,345
-100 Reduced 5.71%
1,651 $363,000
Q3 2021

Nov 08, 2021

BUY
$181.39 - $202.99 $13,060 - $14,615
72 Added 4.29%
1,751 $318,000
Q2 2021

Aug 10, 2021

SELL
$187.49 - $221.1 $3,749 - $4,422
-20 Reduced 1.18%
1,679 $339,000
Q1 2021

May 11, 2021

BUY
$207.02 - $241.31 $351,726 - $409,985
1,699 New
1,699 $365,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Marcum Wealth, LLC Portfolio

Follow Marcum Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marcum Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Marcum Wealth, LLC with notifications on news.